GLP-3 RTA Triple G Pen delivers 40mg of Reta; a triple GLP-1/GIP/Glucagon receptor agonist in a convenient adjustable dose pre filled injection pen. Researched for superior body weight reduction, visceral fat loss, improved insulin sensitivity, and enhanced energy expenditure compared to single and dual incretin agonists. Precise adjustable dosing with no reconstitution required, same day dispatch from within Canada.
FormatPre Filled Pen
Concentration40mg Adjustable Dose
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
GLP-3 RTA (Triple G) is a triple incretin receptor agonist simultaneously targeting glucagon like peptide 1 (GLP-1), glucose dependent insulinotropic polypeptide (GIP), and glucagon receptors. The most advanced incretin based research compound in CSD’s metabolic peptide range. F40 Biotech’s 40mg adjustable dose pen delivers this triple receptor agonist in a prefilled pen system with dose adjustment capability, a distinct delivery format from both the lyophilized vial presentations and fixed dose pen systems in CSD’s GLP-3 RTA range, providing researchers with the administration convenience of a pen format combined with the dosing flexibility typically associated with reconstitute vial preparations.
The adjustable dose pen format serves a specific research purpose within CSD’s GLP-3 RTA family. Fixed dose pen systems and lyophilized vials each present trade offs between administration convenience and dosing flexibility. The adjustable dose pen addresses both simultaneously, allowing researchers to dial precise dose increments from a single pen supply without reconstitution preparation while maintaining the ability to modify administered dose across the protocol timeline. This is particularly relevant for triple incretin agonist research where dose titration beginning at lower concentrations and escalating based on observed receptor response is a common protocol design approach in metabolic and appetite regulation research examining GLP-1, GIP, and glucagon receptor co activation thresholds.
CSD’s GLP-3 RTA range now spans the most comprehensive concentration and format selection of any incretin agonist compound in our catalogue: lyophilized vials across Hudson Science 20mg, 30mg, 50mg, 60mg and iLab Pharma 40mg, alongside this F40 Biotech 40mg adjustable dose pen. The adjustable dose pen format sits alongside the lyophilized vial options as a complementary rather than competing presentation. Our vials serving in vitro applications and precise reconstitution controlled protocols, the adjustable pen serving repeated parenteral administration research where dose titration flexibility and preparation free convenience are the priority variables.
F40 Biotech formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and F40 Biotech’s GLP-3 RTA Triple G pen meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store at 2–8°C away from direct light. Do not freeze. Keep upright. Intended for research purposes only.
Commonly researched alongside dual incretin agonist compounds and Semaglutide in comparative receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.
Reta is a triple receptor agonist, simultaneously activating GLP-1 (glucagon like peptide 1), GIP (glucose dependent insulinotropic polypeptide), and glucagon receptors. This triple agonism distinguishes it from Semaglutide (GLP-1 single agonist) and Tirzepatide (GLP-1/GIP dual agonist) making Reta the most comprehensive incretin based metabolic research compound currently available. The additional glucagon receptor agonism produces enhanced energy expenditure and hepatic fat mobilization beyond what GLP-1 and GIP agonism alone achieves. Contributing to the superior weight reduction outcomes observed in clinical research versus both Semaglutide and Tirzepatide in comparable timelines.
The 40mg pen at 10 clicks per 1mg provides the largest total Reta content of any pen in CSD's catalogue, up to 40 x 1mg doses or 80 x 0.5mg doses. For a standard gradual titration protocol beginning at 0.5mg weekly and escalating through 1mg, 2mg, 4mg, and 6mg weekly maintenance doses, the 40mg pen covers an extended research protocol well beyond the initial titration phase. For researchers who have reached a 2mg weekly maintenance dose, the pen provides 20 weeks of continuous research. The adjustable dose mechanism allows any combination of doses across the 40mg total. Making this the most flexible and longest duration Reta pen available.
The glucagon receptor agonism component produces several research effects not achieved by GLP-1 or GIP agonism alone. Glucagon receptor activation in the liver increases hepatic glucose production and fatty acid oxidation, enhancing energy expenditure and fat mobilization beyond appetite suppression alone. This produces greater total caloric expenditure compared to GLP-1 single agonists, contributing to superior weight reduction outcomes. The glucagon component also enhances lipolysis in adipose tissue; making Reta particularly researched for visceral and hepatic fat reduction alongside total body weight reduction. The triple agonism mechanism produces the most comprehensive metabolic modulation of any currently researched incretin compound.
Reta is administered subcutaneously once weekly, the same day each week in the abdomen, thigh, or upper arm using a standard pen needle. A gradual dose titration schedule is strongly recommended to minimize gastrointestinal side effects. Beginning at 0.5mg weekly (5 clicks) for 4 weeks, then escalating in 0.5–1mg increments every 4 weeks based on tolerability. The 6 day half-life supports once weekly administration to maintain stable plasma levels. Attach a fresh pen needle before each injection and dispose safely after use — do not store the pen with a needle attached between injections.
Yes! This batch has been independently HPLC tested by an accredited third party laboratory confirming compound identity and concentration accuracy at 40mg total content with 0.1mg per click delivery. A certificate of analysis is available.
![GLP-3 RTA [Triple G] 40mg injection pen for adjustable dosing and research on weight management, metabolic performance, and glucose regulation in Canada](https://www.canadasteroiddepot.is/wp-content/uploads/2025/06/F40-GLP3-40MG-PEN-600x600.webp)
![GLP-3 RTA [Triple G] 40mg injection pen for adjustable dosing and research on weight management, metabolic performance, and glucose regulation in Canada](https://www.canadasteroiddepot.is/wp-content/uploads/2025/06/F40-GLP3-40MG-PEN-100x100.webp)